Microvascular Arteriovenous Shunting is a Probable Pathogenetic Mechanism in Erythromelalgia
نویسندگان
چکیده
منابع مشابه
Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia.
Erythromelalgia is a condition consisting of red, warm, and burning painful extremities. Symptoms are relieved by cold and aggravated by heat. A wide variety of etiologic conditions can cause erythromelalgia, but one common pathogenetic mechanism, microvascular arteriovenous shunting, has been hypothesized. The aim of this study was to test this hypothesis. Quantification of skin microvascular ...
متن کاملErythromelalgia – A condition caused by microvascular arteriovenous shunting
Chapter 1 Introduction Erythromelalgia (EM) is a rare disorder characterized by red, warm and painful extremities. In what superficially appears to be the antithesis of Raynaud's disease, victims of EM seek relief by cooling of the affected extremity. Over the years terms such as erythermalgia [1], and erythralgia [2] have also been used for the condition. Graves [3] reported the first case of ...
متن کاملReduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism.
Erythromelalgia is characterized by burning pain, erythema, and increased temperature in acral skin. The pain is aggravated by warming and relieved by cooling. Increased microvascular arteriovenous shunting in deep dermal plexa has been hypothesized as the pathogenetic mechanism of pain in affected skin, inducing hypoxia during pain attacks. The aim of this study was to quantify skin capillary ...
متن کاملThe prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study.
Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by treatment with misoprostol (0.4-0.8 mg per d), both for 6 wk. The patients (n=21) and a study nurse who administered the trial were blinded. The endpoints were change in ...
متن کاملThe prostaglandin E1 analog misoprostol reduces symptoms and microvascular shunting in erythromelalgia – a double-blind, crossover, placebo-compared study
Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by treatment with misoprostol (0.4-0.8 mg per d), both for 6 wk. The patients (n = 21) and a study nurse who administered the trial were blinded. The endpoints were change i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Investigative Dermatology
سال: 2000
ISSN: 0022-202X
DOI: 10.1046/j.1523-1747.2000.00944.x